YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential
YH003 in combination with PD-1 are being dosed in phase II multi-regional clinical trials sponsored by Eucure Biopharma for pancreatic cancer and melanoma in Australia, the US and China
ISU ABXIS intends to deploy YH003 sequence to develop tri-specific antibody for the treatment of multiple tumor types
Eucure Biopharma based clinical-stage biotechnology company focused on the development of antibody therapeutics, announced today that it has entered into a collaborative agreement with ISU ABXIS Co., Ltd. (KOSDAQ: 086890), a Korea-based clinical stage company developing immuno-oncology drugs.
Under the terms of the agreement, ISU ABXIS will utilize the sequence of YH003, Biocytogen
